Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Greek Capital Controls Stop Supplier Payments: Mavrikos
06:21 - Greek capital controls have meant Mavrikos Imports SA has been unable to pay suppliers and is having to stop producing, according to managing director Nick Mavrikos. He spoke in an interview with Guy Johnson in Athens on Bloomberg Television's "Countdown." (Source: Bloomberg)
  • A ‘No’ Vote Doesn’t Mean a ‘Grexit’: Saywell
  • Greeks Split Down Middle Before Referendum
  • Greeks Split Evenly on Austerity: Bloomberg Poll